Angelica Welch

Articles

New Data Further Demonstrate PARP Inhibitor Impact in Ovarian Cancer

November 29th 2018

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

Burtness Breaks Down Pembrolizumab Data in HNSCC

November 26th 2018

Barbara A. Burtness, MD, discusses the impact that the KEYNOTE-048 data could have on the treatment of patients with head and neck squamous cell carcinoma.

Specificity in NSCLC Treatment Grows With Acceptance of NGS and cfDNA

November 21st 2018

Benjamin P. Levy, MD, discusses optimal strategies for molecular interrogation of non–small cell lung cancer.

Rudin Reflects on Recent Data in SCLC

November 21st 2018

Charles M. Rudin, MD, PhD, reflects on the latest developments in small cell lung cancer.

Cognitive Outcomes Improved With Proton Therapy in Pediatric Brain Tumors

November 19th 2018

Favorable neurocognitive outcomes were observed in pediatric patients with brain tumors with the use of proton radiation therapy compared with X-ray radiation therapy.

Addressing De-Escalation of Treatment in HER2+ Breast Cancer

November 15th 2018

Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer.

Novel Targeted Agents Emerging in Ovarian Cancer

November 15th 2018

Diana P. English, MD, discusses the promise for ADCs in the landscape of ovarian cancer treatment and targeting p53 mutations in patients with ovarian cancer.

New Approaches to Localized Prostate Cancer Combat Overtreatment

November 14th 2018

Mark Emberton, MD, FRCS, discusses updates in the diagnosis and treatment of patients with localized prostate cancer.

Future of MCL Treatment May Lie in Combinations, CAR T-Cell Therapy

November 14th 2018

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer

November 12th 2018

The FDA has granted a priority review designation to a supplemental new drug application for olaparib tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Expert Breaks Down Data With TKI Discontinuation in CML

November 10th 2018

Meagan A. Jacoby, MD, PhD, discusses treatment-free remissions in patients with chronic-phase chronic myeloid leukemia.

Rosenberg Reflects on Immunotherapy Developments in Urothelial Carcinoma

November 10th 2018

Jonathan E. Rosenberg, MD, discusses the extended follow-up of the CheckMate-032 study, as well as the future of immunotherapy in urothelial carcinoma.

Drilon Sheds Light on Lesser-Known Markers in NSCLC

November 9th 2018

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

Infigratinib Findings in IHC Highlight Importance of Molecular Testing

November 1st 2018

Milind Javle, MD, discusses findings from a phase II study of infigratinib in patients with intrahepatic cholangiocarcinoma, emphasizing the importance of molecular testing.

Role of Immunotherapy May Expand in Gastric/GEJ Cancers

October 31st 2018

The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.

Real-World Results Reveal Regorafenib Tolerability in mCRC

October 29th 2018

Juan Manuel O’Connor, MD, discusses the final results of the CORRELATE regorafenib study in patients with metastatic colorectal cancer, emphasizing the importance of real-world data.

Benefit of Extended Adjuvant Endocrine Therapy Remains Unknown

October 29th 2018

In a presentation during an OncLive® State of the Science Summit™, Melanie Majure, MD, discussed the duration of endocrine-directed therapy for estrogen receptor–positive breast cancer.

Understanding the Impact of Biosimilars on a Global Scale

October 29th 2018

Martina Weise, MD, discusses the journey of biosimilars as supportive care for patients with cancer, as well as the future of their use as treatment.

Immunotherapy Breaks Through in Breast Cancer

October 27th 2018

Peter Schmid, MD, PhD, shares the results of IMpassion130 and discussed his thoughts on the future of immunotherapy in breast cancer.

Expert Anticipates Bright Future for Immunotherapy in HNSCC

October 25th 2018

Ezra Cohen, MD, discusses the future role of immunotherapy in the treatment of patients with head and neck squamous cell carcinoma.